Long-term safety study of remibrutinib for hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the full 68-week treatment in a previous remibrutinib study for HS.
- You cannot have stopped treatment early in that previous study due to side effects or other reasons.
- You cannot use any other medications for HS or other conditions that are not allowed during this study.
- You must not have any other serious or uncontrolled health problems that would make participation unsafe.
- You must agree to follow the study rules and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
This study tests a cream called ruxolitinib for people with hidradenitis suppurativa (HS). The goal is to see how much of the cream is absorbed when it's applied to a large area of the body.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.